BCRX – biocryst pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing [Yahoo! Finance]
BioCryst to Report First Quarter 2024 Financial Results on May 6
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Form ARS BIOCRYST PHARMACEUTICALS For: Dec 31
Form DEFA14A BIOCRYST PHARMACEUTICALS
Form DEF 14A BIOCRYST PHARMACEUTICALS For: Jun 12
Form 4 BIOCRYST PHARMACEUTICALS For: Mar 31 Filed by: Thackray Helen M.
Form 4 BIOCRYST PHARMACEUTICALS For: Feb 29 Filed by: MILANO VINCENT
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.